ASH 2015 - Leukemia

Blinatumomab Treatment in Adult Patients with Relapsed/Refractory Ph+ ALL: Results from the Phase 2 ALCANTARA Trial

Conference Correspondent - ASH 2015 - Leukemia

Despite the incorporation of tyrosine kinase inhibitors (TKIs) into treatment regimens, patients with relapsed/refractory Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis, underscoring the need for novel treatment strategies. Blinatumomab is a bispecific T-cell engaging (BiTE®) CD19-directed [ Read More ]

Addition of Rituximab to Chemotherapy in Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor ALL: Results of the Randomized Graall-R 2005 Study

Conference Correspondent - ASH 2015 - Leukemia

The anti-CD20 monoclonal antibody rituximab is an integral component of chemoimmunotherapy regimens in B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (ALL). However, its role in B-cell precursor (BCP)-ALL has not been established in randomized studies. Maury and colleagues [ Read More ]

Intermediate-Dose Cytarabine/Mitoxantrone versus Standard-Dose Cytarabine/Daunorubicin Induction Therapy in AML Patients >60 Years: Results from the SAL 60+ Trial

Conference Correspondent - ASH 2015 - Leukemia

Intensive induction chemotherapy consisting of daunorubicin plus cytarabine (DA) is the standard of care for patients with acute myeloid leukemia (AML); however, elderly patients experience high treatment-related morbidities and lower remission rates than younger patients, underscoring the need for active [ Read More ]

Clofarabine-Based Consolidation in Younger Adults with AML in First Remission: Results of the Randomized ALFA-0702/CLARA Study

Conference Correspondent - ASH 2015 - Leukemia

The randomized ALFA-0702/CLARA study is evaluating the CLARA combination of clofarabine plus intermediate-dose cytarabine versus high-dose cytarabine (HiDAC) as consolidation cycles in younger patients with unfavorable acute myeloid leukemia (AML); Thomas and colleagues reported preliminary results of this trial.1 In [ Read More ]

Single-Agent Clofarabine versus Standard Daunorubicin/Cytarabine Regimen As Induction and Consolidation Therapy in Older Adults with Newly Diagnosed AML: Results of the Phase 3 E2906 Trial

Conference Correspondent - ASH 2015 - Leukemia

The standard induction therapy for older adults (age ?60 years) with newly diagnosed acute myeloid leukemia (AML) is daunorubicin plus cytarabine (DA). Clinical evidence indicates that a non–cytarabine-based regimen such as single-agent clofarabine induction and consolidation therapy is associated with [ Read More ]

Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory ALL Treated with Blinatumomab

Conference Correspondent - ASH 2015 - Leukemia

Blinatumomab is a novel bispecific T-cell engaging immunomodulatory antibody that is approved for relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL).1 Blinatumomab therapy is associated with infections and cytokine release syndrome (CRS); fever is a clinical indicator for both. This single-center [ Read More ]